Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for halo
+0.29 (1.64%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.70 - 18.27
52 week 7.51 - 25.25
Open 17.77
Vol / Avg. 0.00/1.30M
Mkt cap 2.30B
P/E     -
Div/yield     -
EPS -0.33
Shares 128.01M
Beta 1.60
Inst. own 78%
Dec 8, 2015
Halozyme Therapeutics Inc at Oppenheimer Healthcare Conference - 1:00PM EST - Add to calendar
Dec 2, 2015
Halozyme Therapeutics Inc at Piper Jaffray Healthcare Conference - 9:30AM EST - Add to calendar
Nov 11, 2015
Halozyme Therapeutics Inc at Credit Suisse Healthcare Conference
Nov 9, 2015
Q3 2015 Halozyme Therapeutics Inc Earnings Call
Nov 9, 2015
Q3 2015 Halozyme Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -117.71% -90.76%
Operating margin -111.82% -83.68%
EBITD margin - -81.34%
Return on average assets -58.96% -51.07%
Return on average equity -239.21% -640.16%
Employees 153 -
CDP Score - -


11388 Sorrento Valley Rd
SAN DIEGO, CA 92121-1345
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Officers and directors

Kathryn E. Falberg Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Helen I. Torley President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Laurie Stelzer Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Harry J. Leonhardt Esq. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 56
Bio & Compensation  - Reuters
Athena Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 42
Bio & Compensation  - Reuters
Jeffrey W. Henderson Director
Age: 49
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Kenneth J. Kelley Independent Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Randal J. Kirk Independent Director
Age: 61
Bio & Compensation  - Reuters
Connie L. Matsui Independent Director
Age: 61
Bio & Compensation  - Reuters